Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors.
Bungard, C.J., Williams, P.D., Schulz, J., Wiscount, C.M., Holloway, M.K., Loughran, H.M., Manikowski, J.J., Su, H.P., Bennett, D.J., Chang, L., Chu, X.J., Crespo, A., Dwyer, M.P., Keertikar, K., Morriello, G.J., Stamford, A.W., Waddell, S.T., Zhong, B., Hu, B., Ji, T., Diamond, T.L., Bahnck-Teets, C., Carroll, S.S., Fay, J.F., Min, X., Morris, W., Ballard, J.E., Miller, M.D., McCauley, J.A.(2017) ACS Med Chem Lett 8: 1292-1297
- PubMed: 29259750
- DOI: https://doi.org/10.1021/acsmedchemlett.7b00386
- Primary Citation of Related Structures:
6B36, 6B38, 6B3C, 6B3F, 6B3G, 6B3H - PubMed Abstract:
Using the HIV-1 protease binding mode of MK-8718 and PL-100 as inspiration, a novel aspartate binding bicyclic piperazine sulfonamide core was designed and synthesized. The resulting HIV-1 protease inhibitor containing this core showed an 60-fold increase in enzyme binding affinity and a 10-fold increase in antiviral activity relative to MK-8718 .
Organizational Affiliation:
Merck & Co., Inc., 770 Sumneytown Pike, PO Box 4, West Point, Pennsylvania 19486, United States.